Sharon Mavroukakis

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study”.

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

The Lancet(2024)10.1016/s0140-6736(24)00746-3

N/A

1.4DataRank · unranked

60 citations

John H. Baird, Anne Marijn Kramer, Hrishikesh K. Srinagesh, Shabnum Patel, Annie Kathleen Brown +43 more

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia

Journal of Clinical Oncology(2022)10.1200/jco.22.01076

N/A

0DataRank · unranked

73 citations

Anne Eaton, Christina Baggott, Jenna Rossoff, Snehit Prabhu, Amy K. Keating +26 more

Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2531

N/A

0DataRank · unranked

2 citations

Maria Pia Morelli, Massimo Fantini, Marı́a M. Fergusson, Sharon Mavroukakis, Anjum Zaki +4 more

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

Blood Advances(2021)10.1182/bloodadvances.2021006418

N/A

0DataRank · unranked

113 citations

Jaap Jan Boelens, Audrey Mauguen, Christina Baggott, Snehit Prabhu, Emily Egeler +27 more

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14515

N/A

0DataRank · unranked

0 citations

Christopher B. Cole, Ann McCoy, Massimo Fantini, Sharon Mavroukakis, Anjum Zaki +4 more

Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2530

N/A

0DataRank · unranked

2 citations

Massimo Fantini, Kwong Y. Tsang, Kevin C. Conlon, Charalampos S. Floudas, Azam Ghafoor +8 more

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL

Blood Advances(2023)10.1182/bloodadvances.2022008893

N/A

0DataRank · unranked

29 citations

Stephanie J. Si Lim, Kyle Ishikawa, Alexandra Dreyzin, Anant Vatsayan, John J. Chen +28 more